GoodRx Holdings, Inc.

NASDAQ:GDRX

Medical - Healthcare Information Services

Healthcare
$3.36 +1.72%

+$0.05 today

Market cap
$1.15B
Beta
1.61
P/E (TTM)
44.0
EPS (TTM)
$0.06
52W Low $1.77High $5.81

Volume 0.66M

Average 1.61M

GDRX EBITDA Margin

EBITDA as a percentage of revenue.

GoodRx Holdings, Inc.NASDAQ: GDRX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 19.2%

EBITDA Margin was 19.2% in Q1 FY2026, down 4.6 pp from a year earlier. On a trailing-twelve-month basis it was 22.0%, up 0.5 pp year over year. Over 3 fiscal years it widened by 14.6 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 36.0% for the fiscal year ending Dec 2026, up from 23.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
19.2%-5.3 pp QoQ
Last fiscal yearDec 2025
23.1%+3.7 pp YoY
LTMMar 2026
22.0%+0.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-4.6 pp+14.3 pp+18.8 pp
1 year+3.7 pp+12.8 pp+9.1 pp
3 years+14.6 pp+12.9 pp-1.7 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
23.1%
Year-over-year change
+3.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How GDRX compares with its peers on the latest reported figures

  • GDRX's LTM Mar 2026 EBITDA Margin of 22.0% is the highest of the 4 companies compared; the peer median is -1.9%.
  • Its year-over-year change of +0.5 pp is the 3rd highest of 4, against a peer median of +1.0 pp.
  • Over three fiscal years its change of +14.6 pp compares with a peer median of +31.6 pp.
GDRX Competitors Peer median
EBITDA Margin for GDRX and competitors
Company Period LTM level YoY 3-year change
GDRXGoodRx Holdings, Inc.LTM Mar 202622.0% +0.5 pp+14.6 pp
TDOCTeladoc Health, Inc.LTM Mar 20262.3% +1.0 pp+6.1 pp
LFMDLifeMD, Inc.LTM Mar 2026-1.9% -3.3 pp+31.6 pp
AMWLAmerican Well CorporationLTM Mar 2026-22.3% +24.7 pp+64.4 pp
Peer median (excluding GDRX) -1.9%+1.0 pp+31.6 pp

Competitors are the stored peer set for GDRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue745.42M766.55M750.27M792.32M796.85M
Cost of Revenue46.72M65.08M66.93M48.22M57.6M
Gross Profit698.71M701.48M683.34M744.11M739.26M
Gross Margin93.7%91.5%91.1%93.9%92.8%
Research & Development125.86M143.14M135.84M123.75M121.03M
Selling, General & Admin524.9M502.42M466.84M484.98M445.52M
Operating Expenses685.3M699.74M710.35M678.26M651.76M
Depreciation & Amortization34.54M54.18M107.67M69.54M85.22M
EBITDA48M65.19M108.82M153.92M184.36M
EBITDA Margin6.4%8.5%14.5%19.4%23.1%
Operating Income13.41M1.74M(27.01M)65.85M87.49M
Operating Margin1.8%0.2%-3.6%8.3%11.0%
Interest Income59K9.27M32.17M23.27M10.93M
Interest Expense23.64M34.24M56.73M52.92M42.61M
Other Income / Expenses(23.58M)(24.97M)(28.57M)(34.39M)(30.95M)
Income Before Tax(10.18M)(23.23M)(55.57M)31.46M56.54M
Pre-Tax Margin-1.4%-3.0%-7.4%4.0%7.1%
Income Tax Expense15.08M9.6M(46.7M)15.07M26.1M
Net Income(25.25M)(32.83M)(8.87M)16.39M30.44M
Net Margin-3.4%-4.3%-1.2%2.1%3.8%
EPS (Basic)(0.06)(0.08)(0.02)0.040.09
EPS (Diluted)(0.06)(0.08)(0.02)0.040.09
Weighted Avg Shares409.98M412.86M410.32M385.74M356.33M
Weighted Avg Shares (Diluted)409.98M412.86M410.32M392.17M356.97M

GoodRx Holdings, Inc.

NASDAQ:GDRX

Intrinsic Alpha fair value

Locked

Current Price

$3.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.